UPL Limited — PPTs, 11-05-2026: Investor Presentation

UPL delivered a robust FY26, beating guidance with revenue up 11% to ₹51,839 Cr and EBITDA rising 18% to ₹9,588 Cr, improving margins to 18.5%. Growth was volume-led across key markets and platforms like UPL Corp and Advanta. Operational PATMI surged over 2.5 times to ₹1,860 Cr.

Strategically, UPL focuses on expanding its sustainable and differentiated product portfolio, including biosolutions and ProNutiva. Innovation in new hybrids and advanced chemistries, enhanced channel engagement, and optimizing manufacturing for cost leadership are key drivers. Recent achievements include refinancing a ₹2,845 Cr loan and fully repaying a ₹3,794 Cr loan, securing ₹1,897 Cr from a rights issue, and a rating upgrade. New product launches contributed approximately ₹1,517 Cr in revenue.

For Q1FY27, UPL projects 10-14% revenue growth and 14-18% EBITDA growth. Management priorities include continued deleveraging, improving cash conversion, and scaling high-margin products while optimizing costs.